UK’s first brain health clinic opens in Manchester

Key Points

• Manchester Brain Health Centre (MBHC) launched on Monday 21st September 2026 – World Alzheimer’s Day – as the first ever integrated brain health center in the UK, focusing on the early diagnosis and prevention of dementia.
• This is the pilot phase that will run for two years in collaboration between Alzheimer’s Society and Manchester University NHS Foundation Trust, Greater Manchester Mental Health NHS Foundation Trust, University of Manchester and NHS Greater Manchester.
• At MBHC, a range of professionals including psychiatrists, vascular specialists, clinical academics among others will offer same day advanced diagnostic services, which include MRI scans, lumbar punctures, cardiovascular screening, and behavioral testing.
• Those suffering from mild cognitive impairment (MCI) or early dementia will be referred from their existing memory assessment services; eligible patients may join research and trials as well.
• Alzheimer’s Society Brain Health Advisers will also collaborate with NHS healthcare professionals to offer tailored advice on health and lifestyle to help reduce risks of dementia like high blood pressure.
• It has been described as a game-changing model and scalable, which aims at developing the evidence required for national roll-out of brain health centers across the country.

Manchester (Manchester Mirror) September 21, 2026 – The UK’s first dedicated brain health clinic has opened in Manchester, marking a significant shift toward earlier diagnosis, risk reduction and personalised support for people experiencing memory and thinking changes. The Manchester Brain Health Centre (MBHC) launched on World Alzheimer’s Day as a two-year pilot designed to test a fully integrated, one-stop service that could be replicated across the NHS if results prove successful.

What services will the Manchester Brain Health Centre provide?

The MBHC operates as a single, joined-up service that consolidates specialist expertise under one roof to accelerate diagnosis and tailor interventions. As reported by Manchester University NHS Foundation Trust, the centre combines psychiatrists, vascular specialists, clinical academics and allied health professionals to conduct advanced diagnostics in a coordinated pathway. Patients will access MRI scans, lumbar punctures, cardiovascular assessments and behavioural testing, enabling clinicians to identify underlying causes of cognitive symptoms and stratify risk more accurately.

Beyond diagnosis, the clinic emphasises prevention and long-term management. Alzheimer’s Society Brain Health Advisers will work alongside NHS staff to deliver practical guidance on modifiable risk factors – including blood pressure control, physical activity, diet and other lifestyle changes – that research suggests could prevent or delay a substantial proportion of dementia cases. For those with mild cognitive impairment (MCI) or early dementia, the service aims to stabilise or slow decline by addressing health conditions that contribute to brain vulnerability.

Who can access the clinic and how will patients be referred?

Access to the MBHC is via referral from existing memory assessment services, ensuring that people already in the diagnostic pathway can be fast-tracked into the enhanced pilot. Individuals who meet the centre’s criteria will be identified through these services and referred directly for comprehensive assessment. This design seeks to reduce delays between first presentation of symptoms and definitive diagnosis – a longstanding bottleneck in dementia care.

Participants in the central Manchester pilot will also have the opportunity, where eligible, to enrol in research studies and clinical trials. By embedding research within routine care, the MBHC intends to accelerate evidence generation on early interventions and create a pipeline for testing new therapies in a real-world clinical setting.

Which organisations are leading the pilot and what do they say?

The pilot is spearheaded by Alzheimer’s Society in collaboration with Manchester University NHS Foundation Trust, Greater Manchester Mental Health NHS Foundation Trust, the University of Manchester, and with support from NHS Greater Manchester. Michelle Dyson CB, Chief Executive Officer of Alzheimer’s Society, said dementia is the UK’s biggest killer but not an inevitable part of ageing, noting that nearly half (45%) of dementia cases worldwide could be prevented or delayed by addressing health and lifestyle factors across the life course. “If we can identify people early enough, we can significantly improve their brain health and help put the brakes on dementia,” Dyson said, adding that the Manchester model “could be replicated in other regions, transforming the future for thousands of people at risk of dementia or in the early stages of memory loss.”

Professor Adam Greenstein, Consultant Geriatrician at Manchester University NHS Foundation Trust and Clinical Scientist at the University of Manchester, described the centre as a “game-changing approach” that unites partners committed to earlier diagnosis and better outcomes. “We are combining clinical and research expertise to identify people earlier, address risk factors such as high blood pressure, and support patients to live better for longer,” Greenstein said, stressing that the pilot will generate evidence to inform future service development nationwide.

Dr Ross Dunne, Consultant Later Life Psychiatrist and Dementia Research Lead at Greater Manchester Mental Health NHS Foundation Trust, said the current system is not optimised for the point at which memory and thinking problems first appear – precisely when early diagnosis and treatment could have the greatest impact. “We want the UK to be the best place in the world to get an early and accurate diagnosis,” Dunne said, outlining ambitions for the UK to lead global dementia research and for the MBHC model to inform brain health clinics across the country.

What do patients and carers say about the need for earlier diagnosis?

Dr Helen Beaumont, whose husband Clive was diagnosed with Young Onset Dementia at 46 and died at 51, highlighted the human cost of delayed diagnosis. “Looking back now, it is clear that the signs were there for a while,” Beaumont said, recounting how Clive first sought help at 40 for difficulties with reading and writing but was reassured it was nothing serious. As symptoms progressed, he lost his job and gradually became unable to perform everyday tasks, with the family spending years searching for answers.

“When Clive was finally diagnosed with Young Onset Dementia, he was just 46. It took years to receive a diagnosis, and when we did, it was given to us over the phone from a consultant – after that we were largely left on our own,”

Beaumont said. She added that an earlier and more accurate diagnosis can help people understand what is happening, access support sooner and, increasingly, open the door to treatments and research opportunities.

“If a service like the Manchester Brain Health Centre had existed when Clive first began experiencing symptoms, it would have made an enormous difference to him and to our family,”

she said.

Where is the clinic located and what is the pilot’s duration?

The MBHC pilot clinic is hosted at the National Institute for Health and Care Research (NIHR) Clinical Research Facility (CRF): Manchester at Manchester Royal Infirmary. The two-year timeframe is intended to allow sufficient data collection on diagnostic pathways, patient outcomes and service efficiency to determine whether the model should be scaled. Organisers describe the centre as a scalable prototype that could be adopted more widely across the NHS pending evaluation.

Background of the particular development

The launch of the Manchester Brain Health Centre follows years of pressure to shorten diagnostic delays and integrate prevention into dementia care. Around one million people are living with dementia in the UK, yet at any time approximately a third do not have a formal diagnosis, according to figures cited by partners in the pilot. International research indicates that modifiable risk factors – including hypertension, hearing loss, smoking, physical inactivity and social isolation – contribute substantially to dementia incidence, underpinning the rationale for a clinic that combines rapid assessment with risk-reduction support. The MBHC builds on existing memory services but adds vascular and behavioural expertise, advanced biomarker-capable diagnostics and embedded research capacity to create a more proactive, preventative model.

Prediction: how this development can affect people with memory concerns and the NHS

If the MBHC demonstrates earlier diagnosis, better risk management and improved patient experience, the most immediate effect is likely to be shorter waits and clearer care pathways for people with mild cognitive impairment and early dementia in Greater Manchester. For patients and families, earlier answers could reduce uncertainty, enable timely access to support and, where appropriate, entry into clinical trials. For the NHS, a successful pilot could justify investment in similar multidisciplinary brain health clinics in other regions, potentially shifting resources toward prevention and early intervention to reduce long-term care costs. However, scaling will depend on workforce capacity, diagnostic infrastructure and sustained funding factors that will be scrutinised as the two-year evaluation progresses.